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Abstract
Background: Chemotherapy resistance remains a major obstacle for the treatment of small cell
lung cancer (SCLC). Glucose-regulated protein 78 (GRP78), an endoplasmic reticulum chaperone,
plays a critical role in chemotherapy resistance in some cancers. However, whether the
suppression of the chaperone can enhance the sensitivity of chemotherapy in SCLC is still unclear.
Methods: The SCLC NCI-H446 cells were divided into three groups: BAPTA-AM→A23187-
treated group, A23187-treated group and control-group. Immunofluorescence, western blot and
RT-PCR were used to assess the expression of GRP78 at both protein and mRNA levels. Cell
apoptosis and the cell cycle distributions of the cells were analyzed by flow cytometry in order to
evaluate the therapeutic sensitivity to VP-16.
Results: The expression of GRP78 at both protein and mRNA levels in the BAPTA-AM→A23187-
treated cells dramatically decreased as compared to that in both A23187-treated and control
groups. After treatment by VP-16, the percentage of apoptotic cells in BAPTA-AM→A23187-
treated cells were: 33.4 ± 1.01%, 48.2 ± 1.77%, 53.0 ± 1.43%, 56.5 ± 2.13%, respectively,
corresponding to the concentrations of BAPTA-AM 10, 15, 25, 40 μM, which was statistically
significant high in comparison with the A23187-treated group and untreated-group (7.18 ± 1.03%
and 27.8 ± 1.45%, respectively, p < 0.05). The results from analysis of cell cycle distribution showed
that there was a significantly decreased in G1 phase and a dramatically increased in S phase for the
BAPTA-AM→A23187-treated cells as compared with the untreated cells.
Conclusion: BAPTA-AM is a strong inhibitor of GRP78 in the NCI-H446 cell line, the down-
regulation of GRP78 can significantly increase the sensitivity to VP-16. The suppression of GRP78
may offer a new surrogated therapeutic approach to the clinical management of lung cancer.
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Background
Lung cancer is currently the leading cause of cancer deaths
worldwide no matter in men or women [1]. Small cell lung
cancer (SCLC) accounts for 13%–15% of all lung cancer
worldwide [2]. Chemotherapy is an important means of
the treatment for patients with SCLC. However, the drug
resistance as developed during the treatment really limits
the efficacy of chemotheraspy. Multiple pathways are sug-
gested to be involved in the complexity of chemotherapy
resistance in SCLC. A favorable mechanism for explaining
the chemotherapy resistance is speculated as the presence
of microenvironment conditions, glucose starvation and
hypoxia that occur naturally in solid tumors [3]. Cells
respond to these stressful conditions through the synthesis
of a kind of evolutionarily conserved protein, named as
glucose-regulated proteins (GRPs) [4], which are known to
show the protective role as a molecular chaperone against
endoplasmic reticulum (ER) stress-induced cell death in
mammalian cells [5-7]. GRP78/BiP, a well-characterized
GRP member with molecular weight of 78 kda, belongs to
the highly conserved heat shock protein 70 (HSP70) fam-
ily, resides primarily in ER of mammalian cells [8,9]. It can
be regulated by several cellular stresses which perturb ER
function and homeostasis including some inhibitors and
inducers [10]. Generally, the commonly used inducers are
2-deoxyglucose, tunicamycin and calcium ionophore
A23187; the commonly used inhibitors are thapsigargin
and membrane-permeant Ca2+  chelator BAPTA-AM
[11,12]. A line of studies have shown that GRP78 plays a
protective role in maintaining cell viability against several
kinds of stress in a variety of cancers [13-15]. In our recent
study, we demonstrated that the overexpression of GRP78
under the induction of A23187 is associated with chemo-
therapy resistance to VP-16 in human lung cancer [16,17].
Thus, increasing attention on the role of GRP78 plays in
chemotherapy resistance during therapy has been brought.
However, most of the reports focus on the up-regulation of
GRP78, while whether the suppression of GRP78 could
enhance the sensitivity of chemotherapy in cancer still
remains unclear. Herein, we intended to investigate the
down-regulation of GRP78 by BAPTA-AM, and the func-
tion of the suppression in the resistance to VP-16 in SCLC
NCI-H446 cells.
Methods
Cell culture and treatment
The NCI-H446 cell line was obtained from the American
Type Culture Collection (Manassas, VA, USA) and cul-
tured in RPMI-1640 medium (Sigma-Aldrich Co, St.
Louis, MO, USA) supplemented with 5% fetal bovine
serum (FBS) and 100 μg/ml kanamycin at 37°C in a
humidified atmosphere containing 5% CO2 and 95% air.
The medium was routinely changed 3 days after seeding.
All experiments were performed using exponentially
growing cells and repeated at least 3 times. The cells were
divided into BAPTA-AM→A23187-treated group,
A23187-treated group and control-group. For BAPTA-
AM→A23187-treated group, the cells were exposed to
BAPTA-AM (sigma, St. Louis, MO) at different concentra-
tions of 10,15, 25, and 40 μM, respectively for 2 h before
the addition of A23187 (Sigma Chemical Co,
Taufkirchen, Germany) at the concentration of 2 μM for
24 h; For A23187-treated group, the cells were added
A23187 alone at 2 μM for 24 h; For control-group, the
cells were cultured in medium for 24 h. Cell survival to
VP-16 (Sigma, St. Louis, MO, USA) was determined by
flow cytometry. Briefly, following exposure to BAPTA-AM
or A23187, the cells of the three groups were incubated
with VP-16 at concentration of 30 μM for 6 h, respectively,
then, the cells were cultured in new media for another 48
h further before the harvest for the analysis of apoptosis
and cell cycle using flow cytometry (FAC star; BD Bio-
sciences).
RNA isolation and conventional RT-PCR
Total RNA was extracted from the cells with Trizol
(GIBCO BRL, Gaithersburg, MD, USA) according to the
manufacturer's instructions. In brief, the lysis of the cells
in Trizol was centrifuged at 10000 g at 4°C for 15 min in
the presence of chloroform. The upper aqueous phase was
collected and the RNA was precipitated by addition of
100% isopropanol and a high salt precipitation solution
(0.8 M sodium citrate and 1.2 M NaCl) and centrifuged at
7500 g at 4°C for 5 min. RNA pellets were washed with
ice-cold 75% ethanol, dried, resuspended in sterile water
and quantified by spectrometry. RT-PCR was performed
with an RNA PCR Kit (AMV, Ver.3.0, TaKaRa, Japan)
according to the manufacturer's instructions. The house-
keeping gene, β-actin was used as an internal control to
confirm equal loading in each experiment and was ampli-
fied from the same cDNAs. The primers specific for
GRP78 and β-actin are shown in Table 1. Reverse tran-
scription was performed in a 10 μl volume mixture made
up of 1 μl (≤1 μg) of total RNA, 0.5 μl Oligo dT-Adaptor
primer (2.5 pmol/μl), 1 μl of 10 – Reverse-transcription
buffer, 1 μl dNTP mixture (10 mM each), 0.5 μl AMV
Table 1: Characteristics of primers used for conventional RT-PCR
Genes Sequence of primers Products(bp)
GRP78 5' GATAATCAACCAACTGTTAC 3'
5' GTATCCTCTTCACCAGTTGG 3'
577
β – actin for GRP78 5' TCGTCACCAACTGGGACGACATGG 3'
5' GATCTTGATCTTCATTGTGCTGGG 3'
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Reverse transcriptase XL (5 U/μl) and 0.25 μl RNA ribonu-
clease inhibitor (40 U/μl). Reverse transcription was per-
formed at 42°C for 30 min and terminated at 95°C for 5
min. The PCR reaction was performed in 10 μl of 5 – PCR
buffer, 0.25 μl Taq DNA polymerase (5 U/μl), 10 μl RT
product and 0.5 μl of each primer (20 pmol/μl). The PCR
conditions were as follows: 1 cycle of 94°C for 4 min, 30
cycles of 94°C for 1 min, 58°C for 30 sec, 72°C for 30 sec
and 72°C for 10 min. A total of 8 μl PCR products was
separated on a 1.5% agarose gel and stained with ethid-
ium bromide for visualization. The relative abundance of
each PCR product was determined by quantitative analy-
sis of digital photographs of gels using Labworks 4.6 soft-
ware (UVP Products, Upland, CA, USA). The integral
optical density (IOD) values of GRP78 and the β-actin
were measured. The ratio of IODGRP78/IODβ-actin was used
to express the relative level of GRP78 mRNA.
Immunofluorescence
After treatment, the cells were washed twice with PBS,
fixed with 4% paraformaldehyde in PBS for 10 min, per-
meablized in PBS containing 0.1% Triton X-100 and 5%
bovine serum albumin for 30 min before the detection of
GRP78 with immunofluorescence. The media with anti-
GRP78 (C-20) goat polyclonal antibody (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) at a dilution of 1:1000
were introduced into the culture chamber and the cells
were incubated at 4°C over night. After being washed with
PBS for three times, the cells were stained with anti-goat
FITC green-conjugated secondary antibody (Santa Cruz
Biotechnology, Inc) at a dilution of 1:100 at 37°C for 30
min. Cell images were subsequently captured with fluo-
rescence microscope and analyzed using Northern expo-
sure image analysis/archival software (Mississauga,
Ontario, Canada).
Protein isolation and Western blot
Cells were collected and centrifuged at 4000 rpm for 5
min, the supernatants were discarded before ice-cold RIPA
buffer (PBS, pH 7.4 containing 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS with freshly added 10 mg/ml
Phenylmethanesulphonyl fluoride) was added to the cell
pellets. After a 30 min incubation on ice, samples were
spun at 10444 rpm for 10 min at 4°C and the superna-
tants were collected. Two additional centrifugations were
performed to produce clarified lysates. Protein concentra-
tions of the resulting lysates were determined by Coomas-
sie Brilliant Blue staining. An equivalent of 50 μg protein
in each sample was denatured at 90°C for 5 min, loaded
on a 10% SDS-polyacrylamide gel containing a 4% stack-
ing gel, together with a molecular weight standard (Gibco
BRL, Gaithersburg, MD, USA), and then electrophoresed
at 180 V for 1.5 h in Tris-glycine running buffer (25 mml/
L Tris-base, 250 mmol/L glycine, 0.1% SDS). Proteins
were electroblotted onto a nitrocellulose membrane. The
blotted membrane was blocked with 5% nonfat dry milk
in PBST (PBS, pH 7.4, Tween 20) with gentle shaking at
room temperature overnight and then incubated for 2 h at
room temperature in 1% bovine serum albumin (BAS)/
PBST containing goat-anti-GRP78 polyclonal antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:400)
with gentle shaking. Following being washed in PBST for
three times, the membrane was then incubated for 1 h at
room temperature in 1% BSA/PBST containing the second
antibody (rabbit antigoat IgG, Santa Cruz Biotechnology,
1:1000) with gentle shaking. The membrane was washed
again for three times in PBST. Goat-anti-β-actin polyclo-
nal antibody (43 kDa, Santa Cruz Biotechnology, 1:500)
was used as an internal control. Rabbit anti-goat second-
ary antibody (1:1000) was used subsequently. GRP78
protein expression was detected using an ECL (enhanced
chemiluminescence) Plus kit (Amersham Biosciences, Pis-
cataway, NJ, USA). Signals were visualized by autoradiog-
raphy and determined by quantitative analysis of digital
photographs of gels using Labworks 4.6 software (UVP
Products, Upland, CA, USA). The integral optical density
(IOD) values of GRP78 and β-actin were measured. The
ratio of IODGRP78/IOD β-actin was used to express the
relative level of GRP78 protein.
Analysis of apoptosis
After the treatment with VP-16, the cells were trypsinized,
washed with ice-cold PBS (pH 7.4) for two times and re-
suspended in 1 × binding buffer (10 mM HEPES, pH 7.4,
140 mM NaCl, 2.5 mM CaCl2) at a concentration of 1 ×
106 cells/ml. 100 μl of cell suspension was transferred to
5 ml plastic tubes, 5 μl of annexin V-fluorescein isothiocy-
anate (PharMingen) and 5 μl propidium iodide (PI) were
added. The cells were gently vortexed and incubated in the
dark at room temperature for 25 min. 400 μl of binding
buffer was added to each tube, and annexin V staining was
analyzed within 1 h by flow cytometry (FAC star; BD Bio-
sciences). Cells negatively stained by both PI and annexin
V are considered as live cells, annexin V positive stained
cells are considered as the early apoptotic cells, and both
PI and annexin V positive stained cells are primarily cells
in late stages of apoptosis. The experiments were repeated
two to three times.
Cell cycle analysis
Following seeding, the VP-16-treated cells were
trypsinized and fixed in 70% ethanol. The fixed cells were
treated with PBS containing 0.1% (v/v) Triton X-100, 0.2
mg/ml DNase-free RNase, and 20 g/ml PI for 30 min at
room temperature. The cell cycle distributions were ana-
lyzed by a fluorescence-activated cell sorting (FACS) scan
flow cytometry analysis (FAC star; BD Biosciences) and
data were analyzed with ModFit software. The cell cycle
distribution measurements were repeated three to five
times.BMC Cancer 2008, 8:372 http://www.biomedcentral.com/1471-2407/8/372
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Statistical analysis
The statistical analyses were carried out with SPSS 12.0 for
Windows software. Student's t-test and χ2 test (chi-square
test) were used to compare the results of flow cytometry,
expression of GRP78 mRNA and GRP78 protein respec-
tively. A value of p < 0.05 was regarded as statistically sig-
nificant.
Results
Down-regulation of GRP78 mRNA by BAPTA-AM
To examine the effect of BAPTA-AM on the expression of
GRP78 mRNA in NCI-H446 cell line, we carried out a con-
ventional RT-PCR analysis on the cells in BAPTA-
AM→A23187-treated group, A23187-treated group and
control group. When the cells were exposed to BAPTA-AM
alone at different concentrations (10, 15, 25, and 40 μM)
for 2 h, the signals of GRP78 mRNA were too weak to be
assayed easily with an approximately concentration-
depended manner (date not shown), whereas after the
addition of A23187 at the concentration of 2 μM for 2 h,
the GRP78 mRNA signals of the BAPTA-AM pre-treated
cells could be assayed obviously. Therefore, the cells were
grouped three as above. As shown in Fig. 1, the expression
of GRP78 mRNA in BAPTA-AM→A23187-treated group
was decreased greatly (around 2–4-folds) compared with
that of A23187-treated and control groups, also shown a
nearly BAPTA-AM concentration-dependent manner.
Down-regulation of GRP78 protein by BAPTA-AM
To analyze whether the expression of GRP78 protein was
related to the GRP78 mRNA for the cells pretreated with
BAPTA-AM, we carried out an immunofluorescence and
The results of GRP78 RT-PCR products for the NCI-H446 cells Figure 1
The results of GRP78 RT-PCR products for the NCI-H446 cells. (A): untreated (control) cells; (B-E): cells treated with 
BAPTA-AM at 10 μM (B), 15 μM (C), 25 μM (D), 40 μM (E) for 2 h respectively, prior to the addition of A23187 at 2 μM for 
24 h; (F): cells treated with 2 μM A23187 alone for 24 h. I: Electrophoregram II: Bar graph.BMC Cancer 2008, 8:372 http://www.biomedcentral.com/1471-2407/8/372
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western blots assay on the NCI-H446 cells. The result of
immunofluorescence showed that GRP78 displayed a
perinuclear, reticular pattern of distribution in the cells
(Fig. 2). The expression of GRP78 in BAPTA-
AM→A23187-treated group was obviously weak as com-
pared to the A23187-treated and control groups. The
results from the Western blot analysis agreed well with
that from immunofluorescence and the RT-PCR (Fig. 3).
As shown in Fig. 3, the expression of GRP78 protein in
BAPTA-AM→A23187-treated group was decreased greatly
(around 3-folds) compared with that of A23187-treated
group and control group, with a character of BAPTA-AM
concentration-dependent.
Effect of BAPTA-AM pretreatment on cell resistance to VP-
16
To determine the relationship between the down-regula-
tion of GRP78 and the sensitivity to anti-cancer drug VP-
16 in NCI-H446 cell line, the cells were exposed to VP-16
at 30 μM for 6 h after the pretreatment with BAPTA-AM or
A23187. Trypan blue exclusion assay showed less than 1%
of the cells pretreated with BAPTA-AM at concentrations
from 10 μM to 40 μM died (date not shown), indicating
The expression of GRP78 at the protein level detected by Immunofluorescence in NCI-H446 Figure 2
The expression of GRP78 at the protein level detected by Immunofluorescence in NCI-H446. (A): untreated 
(control) cells; (B): cells treated with 2 μM A23187 alone for 24 h; (C): cells pretreated with BAPTA-AM at 40 μM for 2 h prior 
to the addition of A23187 at 2 μM for 24 h. (D): cells treated with BAPTA-AM at 10 μM alone for 2 h.BMC Cancer 2008, 8:372 http://www.biomedcentral.com/1471-2407/8/372
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that the pretreatment with BAPTA-AM alone did not affect
the cell viability. The percentage of apoptotic cells meas-
ured by flow cytometry showed that the sensitivity to VP-
16 for the cells in BAPTA-AM→A23187-treated group was
significantly higher as compared to both group of
A23187-treated and control. As shown in Fig. 4, the per-
centage of apoptotic cells in BAPTA-AM→A23187-treated
group were: 33.4 ± 1.01%, 48.2 ± 1.77%, 53.0 ± 1.43%,
56.5 ± 2.13% respectively, corresponding to the concen-
trations of BAPTA-AM at 10, 15, 25, 40 μM, respectively,
which was statistically significant high in comparison
with the A23187-treated group and control (7.18 ± 1.03%
and 27.8 ± 1.45%, respectively, p < 0.05). Furthermore,
the percentage of apoptotic cells in BAPTA-AM→A23187-
treated group increased as the increment of a BAPTA-AM
concentration. Together with the results of GRP78 above,
it is suggested that down-regulation of GRP78 could
enhance VP-16 induced apoptosis in NCI-H446 cell line.
Cell cycle distribution
The analysis of cell cycle distributions showed that there
was a significantly decrease in G1 phase and a dramatically
increase in S phase in the BAPTA-AM→A23187-treated
cells as compared with the control cells (p < 0.05, Table
2). On the contrary, there was an increased in G1 phase
and decreased in S phase in the A23187-treated cells.
Combined with the expression of GRP78, it indicated that
the cell cycle distribution can be altered significantly by
up- or down-regulation of GRP78 (p < 0.05), suggesting
that the GRP78 mediated alteration of the sensitivity to
VP-16 may be occurred through the G1/S arrest for the
lung cancer cells.
Discussion
Our investigation brought up several interesting issues.
First, the expression of GRP78 at both levels of the mRNA
and protein was decreased significantly under the inhibi-
The expression of GRP78 at the protein level by western blots in NCI-H446 Figure 3
The expression of GRP78 at the protein level by western blots in NCI-H446. (A): untreated (control) cells; (B): cells 
treated with BAPTA-AM at 10 μM alone for 2 h; (C): cells treated with A23187 at 2 μM alone for 24 h; (D-E): cells treated 
with BAPTA-AM at 25 μM (D), 40 μM (E) for 2 h respectively, prior to the addition of A23187 at 2 μM for 24 h.I: Electropho-
regram II: Bar graph.BMC Cancer 2008, 8:372 http://www.biomedcentral.com/1471-2407/8/372
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tion of BAPTA-AM in the NCI-H460 cell line, and the
reduction of GRP78 showed a BAPTA-AM-dependent
manner (Fig. 1). Secondly, the percentage of VP-16
induced cell apoptosis in the cells pretreated with BAPTA-
AM was significantly higher than that in the cells pre-
treated with A23187 or control cells (Fig. 4). To our best
knowledge, this is the first report on the down-regulation
of GRP78 by BAPTA-AM, including the function of the
suppression in the resistance to VP-16 in SCLC NCI-H446
cells.
GRP78 are Ca2+-binding proteins in the ER, the intracellu-
lar Ca2+ levels have been implicated as potent regulators in
the expression of the GRP78. Cytoplasmic free Ca2+ is
maintained at about 10-7 M by concerting actions of Ca2+
pumps on ER, mitochondria and plasma membranes
[18,19]. Thus, it is a common practice to employ specific
calcium ionophore or Ca2+ pump inhibitor to evaluate the
expression of GRP78 [20]. We previously reported that a
calcium ionophore, A23187, a highly potent ER stress
inducer, could induce the expression of GRP78 genes and
proteins in human lung cancer cell line [16]. The possible
mechanism for GRP78 induction under A23187 is that it
lowers the ER calcium level by releasing calcium stores,
which affects protein secretion and causes accumulation
of protein in the ER [21,22]. Unlike A23187, BAPTA-AM,
the membrane-permeant Ca2+ chelator, is a derivative of
EGTA that specifically binds Ca2+; when modified by an
acetoxymethylester group (AM) it is rendered lipophilic
and thus able to cross the plasma membrane as well as
intracellular membranes, including that of the ER. Once
inside the cell, cellular esterases cleave the AM group,
whereby the molecule is able to bind Ca2+ and is no longer
membrane permeant [23]. In this work, we found that
BAPTA-AM attenuated the expression of GRP78 signifi-
cantly. In line with our results, Juliann and Whei-meih
[24,20] also respectively reported that BAPTA-AM caused
a down-regulation of GRP78 in human breast cancer cell
Measurement of apoptotic cells under VP-16 (30 μM) treatment for 6 h determined by FACS analysis Figure 4
Measurement of apoptotic cells under VP-16 (30 μM) treatment for 6 h determined by FACS analysis. (A): 
untreated (control) cells; (B): cells treated with A23187 at 2 μM for 24 h; (C): cells pretreated with BAPTA-AM at 40 μM for 2 
h prior to the addition of A23187 at 2 μM for 24 h. The cells were labeled with annexin V and PI. Viable cells were those with 
low annexin or no annexin and PI staining (lower left panel). Early stage apoptotic cells were represented by high annexin and 
low PI staining (lower right panel), later stage apoptotic cells were represented by high annexin and high PI staining (upper right 
panel), and necrosis cells were represented by high PI and low annexin staining (upper left panel).
Table 2: Cell cycle distribution and percentage of apoptosis for the BAPTA-AM→A23187-treated, A23187-treated, and untreated cells 
(x ± s) %
Groups Cell cycle distribution Percentage of apoptosis
G0/G1 SG 2/M
BAPTA-AM (40 μM) → A23187 – treated 42.00 ± 1.33 43.50 ± 2.17 14.50 ± 1.56 56.5 ± 2.13
A23187-treated (2 μM) 76.00 ± 1.24 21.40 ± 3.03 2.60 ± 2.14 7.18 ± 1.03
untreated 58.90 ± 1.48 39.00 ± 1.27 2.10 ± 1.15 27.8 ± 1.45
Compared with control (untreated) group, P < 0.05.BMC Cancer 2008, 8:372 http://www.biomedcentral.com/1471-2407/8/372
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line and 9L rat brain tumor cells. However, the mecha-
nism of BAPTA-AM caused GRP78 reduction is still not
clear. Reduction of the intracellular calcium level maybe
one of the possible mechanisms [23].
The apoptotic results from the cells pretreated with
BAPTA-AM or A23187, prior to the addition of VP-16,
showed that, the apoptotic rate of cells with lower level of
GRP78 in the BAPTA-AM→A23187-treated group
increase significantly as compared to A23187-treated
group and control with high or normal level of GRP78,
indicating that the down-regulation of GRP78 by BAPTA-
AM may increase the sensitivity to VP-16 in NCI-H446
cell. Analysis of the cell cycle distributions showed that
there was a great decrease in G1 phase and a dramatic
increase in S phase for BAPTA-AM→A23187-treated
group cells, suggesting that BAPTA-AM may render more
sensitivity to VP-16 through the change of distribution of
cell cycle in NCI-H446 cell. Nowadays, only few reports
are involved on BAPTA-AM associated chemotherapy
resistance. The mechanism for the chemotherapy resist-
ance to VP-16 is complex, multiple pathways are involved.
Topoisomerase IIα is an ATP-dependent nuclear enzyme
that plays important roles in DNA replication and chro-
mosome segregation by its ability to change the topologi-
cal structure of DNA. VP-16 is the topoisomerase
inhibitors, it can interact with the enzyme to stabilize
topoisomerase-DNA complex, blocking strand-passing
activity, thereby resulting in DNA breakage [25]. Further-
more, it had been proposed that the chaperone function
of GRP78 could affect growth factor processing, creating a
cell proliferation block to escape drug killing that only
occurs in cycling cells [26]. Since VP-16 targets S phase
cells [27] and here we confirmed that the inhibition of
BAPTA-AM dramatically increased the percentage of S
phase cells, we proposed that GRP78 might render the
cells sensitive to VP-16-induced apoptosis through alter-
ing the cell cycle distribution in NCI-H446 cell line.
Therefore, GRP78 suppression may become a new focal
point for the cancer therapy.
Conclusion
BAPTA-AM is a strong inhibitor of GRP78 in the NCI-
H446 cell line, the down-regulation of GRP78 can
increase the sensitivity to VP-16 significantly. The suppres-
sion GRP78 may offer a new therapeutic approach to the
clinical management of lung cancer.
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